Beta-Cell Rest: A Strategy for the Prevention of Autoimmune Diabetes

References

• Czamocka B., Ruf J., Ferrand M., Carayon P., Lis-Sitzy S. Purification of the human thyroid peroxidase and its identification as the microsomal antigen involved in autoimmune thyroid diseases. FEBS Letters 1985; 190: 147–51
   PubMed Web of Science ®Google Scholar
• Seto P., Hirayu H., Magnusson R., Gestautas J., Port-Mann L., DeGroot L. J., et al. Isolation of a complementary DNA clone for thyroid microsomal antigen. Homology with the gene for thyroid peroxidase. J. Clin Invest 1987; 80: 1205–8
   PubMed Web of Science ®Google Scholar
• Karlsson F. A., Burman P., Loot L., Mardh S. The major parietal cell antigen in autoimmune gastritis with pernicious anemia is the acid producing H,K-ATPase of the stomach. J Clin Invest 1988; 81: 475–9
   PubMed Web of Science ®Google Scholar
• Toh B-H, Gleeson P. A., Simpson R. J., et al. The 60-to 90-kDa parietal cell autoantigen associated with autoimmune gastritis is a b subunit of the gastric H+/K+-ATPase (proton pump). Proc Natl Acad Sci USA 1990; 87: 6418–22
   PubMed Web of Science ®Google Scholar
• Baekkeskov S., Jan-Aanstoot H., Christgau S., et al. Identification of the 64 K antigen in insulin-dependent diabetes as the GABA-synthesizing enzyme enzyme glutamatic acid decarboxylase. Nature 1990; 347: 151–6
   PubMed Web of Science ®Google Scholar
• Rabin D. U., Pleasic S. M., Shapiro J. A., Yoo-War-Ren H., Oles J., Hicks J. M., et al. Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine phosphatases. J Immunol 1994; 152: 3183–8
   PubMed Web of Science ®Google Scholar
• Winqvist O., Karlsson F. A., Kämpe O. 21-hydroxylase, a major autoantigen in idiopathic Addison's disease. Lancet 1992; 339: 1559–62
   PubMed Web of Science ®Google Scholar
• Bednarek J., Furmaniak L., Wedlock N., et al. Steroid 21-hydroxylase is a major autoantigen involved in adult onset autoimmune Addison's disease. FEBS Letters 1992; 39: 51–5
   Google Scholar
• Winqvist O., Gustafsson J., Rorsman F., Karlsson F. A., Kämpe O. Two different cytochrome P450 enzymes are the adrenal antigens in autoimmune polyendocrine syndrome type I and Addison's disease. J Clin Invest 1993; 92: 2377–85
   PubMed Web of Science ®Google Scholar
• Arif S., Vallian S., Farzaneh F., Zanone M M, James S. L., Pietropaolo M., et al. Identification of 3/3-hydroxysteroid dehydrogenase as a novel target of steroid cell autoantibodies: association of autoantibodies with endocrine autoimmune disease. J Clin Endocrinol Metab 1996; 81: 4439–45
   PubMed Web of Science ®Google Scholar
• Roitt I. M, Doniach D., Campbell P. N., Vaughan Hudson R. Autoantibodies in Hashimoto's disease (lymphadenoid goitre). Lancet 1956; ii: 820–1
   Google Scholar
• Schwartz M. Intrinsic-factor-inhibiting substance in serum of orally treated patients with pernicious anemia. Lancet 1958; ii: 61–2
   Google Scholar
• Pav J., Prague M. D., Jexokova Z., Skrha F. Insulin antibodies. Lancet 1963; ii: 221–2
   Google Scholar
• Palmer J. P., Asplin C. M, Demons P. Insulin autoantibodies in insulin-dependent diabetes before insulin treatment. Science 1983; 222: 1337–9
   PubMed Web of Science ®Google Scholar
• Kohno Y., Hiyama Y., Shimojo N., Niimi H., Naka-Jima H., Hosoya T. Autoantibodies to thyroid peroxidase in patients with chronic thyroiditis: effect of antibody binding on enzyme activities. Clin Exp Immunol 1986; 65: 534–41
   PubMed Web of Science ®Google Scholar
• Burman P., Mardh S., Norberg L., Karlsson F. A. Parietal cell antibodies in pernicious anemia inhibit H+, K+-adenosine triphosphatase, the proton pump of the stomach. Gastroenterology 1989; 96: 1434–8
   PubMed Web of Science ®Google Scholar
• Björk E., Velloso L. A., Kämpe O., Karlsson F. A. GAD autoantibodies in IDDM, stiff-man syndrome, and autoimmune polyendocrine syndrome type I recognize different epitopes. Diabetes 1994; 43: 161–5
   PubMed Web of Science ®Google Scholar
• Furmaniak J., Kominami S., Asawa T., Wedlock N., Colls J., Smith B. R. Autoimmune Addison's disease-evidence for a role of steroid 21-hydroxylase autoantibodies in adrenal insufficiency. J Clin Endocrinol Metab 1994; 79: 1517–21
   PubMed Web of Science ®Google Scholar
• Weetman A. P., McGregor A. M. Autoimmune thyroid disease: further developments in our understanding. Endocr Rev 1994; 15: 788–830
   PubMed Web of Science ®Google Scholar
• Amino N., Mori H., Iwatani Y., et al. High prevalance of transient postpartum thyrotoxicosis and hypothyroidism. N Engl J Med 1982; 306: 849–52
   PubMed Web of Science ®Google Scholar
• Jansson R., Dahlberg P. A., Karlsson F. A. Postpartum thyroiditis. Ballieres Clin Endocrinol Metab 1988; 2: 619–35
   PubMedGoogle Scholar
• Burman P., Kämpe O., Kraaz W., Loot L., Smolka A., Karlsson F. A., et al. A study of autoimmune gastritis in the postpartum period and at a 5 year follow up. Gastroenterology 1992; 103: 934–42
   PubMed Web of Science ®Google Scholar
• Takasu N., Komiya I., Nagasawa Y., Asawa T., Yama-Da T. Exacerbation of autoimmune thyroid dysfunction after unilateral adrenalectomy in patients with Cushing's syndrome due to an adrenocortical adenoma. N Engl J Med 1990; 322: 1708–12
   PubMed Web of Science ®Google Scholar
• Burman P., Tottermann T. H., Oberg K., Karlsson F. A. Thyroid autoimmunity in patients on long term therapy with leukocyte derived interferon. J Clin Endocrinol Metab 1986; 63: 1086–90
   PubMed Web of Science ®Google Scholar
• Gisslinger H., Gilly B., Woloszczuk W., Mayr W. R., Havelec L., Linkesch W., et al. Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha. Clin Exp Immunol 1992; 90: 363–7
   PubMed Web of Science ®Google Scholar
• Atkins M. B., Mier J. W., Parkinson D. R., Gould J. A., Berkman E. M., Kaplan M. M. Hypothyroidism after treatment with interleukin-2 and lymphokine activated killer cells. N Engl J Med 1998; 318: 1557–63
   Google Scholar
• Hall R., Lazarus J. H. Changing iodine intake and the effect on thyroid disease. Br Med J 1987; 294: 721–2
   PubMedGoogle Scholar
• Jansson R., Karlsson F. A., Dahlberg P. A. Thyroxine, methimazole and thyroid microsomal autoantibody titres in hypothyroid Hashimoto's thyroiditis. Br Med J 1985; 290: 11–2
   PubMedGoogle Scholar
• Chiovato L., Marcocci C., Mariotti S., Mori A., Pinche-Ra A. L-thyroxine therapy induces a fall of thyroid microsomal and thyroglobulin antibodies in idiopathic myxedema and in hypothyroid, but not in euthyroid Hashimoto's disease. J Endocrinol Invest 1986; 9: 299–305
   PubMed Web of Science ®Google Scholar
• De Bellis A., Bizzaro A., Rossi R., Paglionico A., Criscuolo T., Lombardi G., et al. Remission of subclinical adrenocortical failure in subjects with adrenal autoantibodies. J Clin Endocrinol Metab 1993; 76: 1002–7
   PubMed Web of Science ®Google Scholar
• Botazzo G. F. Type 1 diabetes mellitus: a chronic autoimmune disease. N Engl J Med 1986; 314: 1360–8
   PubMed Web of Science ®Google Scholar
• Gorsuch A. N., Spencer K. M., Lister J., McNally J. M., Dean B. M., Bottazzo G. F. Evidence for a long prediabetic period in type 1 (insulin dependent) diabetes mellitus. Lancet 1981; ii: 1363–4
   Google Scholar
• Leslie R. D. G., Pyke D. A. Escaping insulin dependent diabetes. Characteristic immunological changes don't invariably lead to disease. Br Med. I 1991; 312: 1103–4
   Google Scholar
• Buschard K., Buch I., Molsted-Pedersen L., Hougard P., Kuhl C. Increased incidence of true type I diabetes during pregnancy. Br Med J 1987; 294: 275–9
   PubMed Web of Science ®Google Scholar
• Nishizuka Y. A novel experimental system of organ-localized autoimmune diseases in the mouse. Acta Pathol Jpn 1982; 32: 211–22, SupplI
   PubMedGoogle Scholar
• Reinhart W., Paul T. L., Allen E. M., Alex S., Yang Y-N, Appel M. C, et al. Effect of L-thyroxine administration on the incidence of iodine induced and spontaneous lymphocytic thyroiditis. Endocrinology 1988; 122: 1179–81
   PubMed Web of Science ®Google Scholar
• Gotf'redsen C. F., Buschard K., Frandsen E. K. Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals. Diabetohgia 1985; 28: 933–5
   PubMed Web of Science ®Google Scholar
• Appel M. C, O'Neil J. J. Prevention of spontaneous diabetes in the BB rat by insulin treatment. Pancreas 1986; 1: 356
   PubMedGoogle Scholar
• Atkinson M. A., MacLaren N. K., Luchetta R. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 1990; 39: 933–7
   PubMed Web of Science ®Google Scholar
• Hernandez A., Zorrilla E., Gershberg H. Serum-insulin in remission of juvenile diabetes. Lancet 1968; ii: 223
   Google Scholar
• Weber B. Glucose-stimulated insulin secretion during ‘remission’ of juvenile diabetes. Diabetohgia 1972; 8: 189–95
   PubMed Web of Science ®Google Scholar
• Leahy J. L., Bonner-Weir S., Weir G. C. Minimal chronic hyperglycemia is a critical determinant of impaired insulin secretion after an incomplete pancreatectomy. J Clin Invest 1988; 81: 1407–14
   PubMed Web of Science ®Google Scholar
• Rossetti L., Giaccari A., DeFronzo R. Glucose toxicity. Diabetes Care 1990; 13: 610–30
   PubMed Web of Science ®Google Scholar
• Eizirik D. L., Sandler S., Palmer J. P. Repair of pancreatic beta-cells. A relevant phenomenon in early IDDM?. Diabetes 1993; 42: 1383–91
   PubMed Web of Science ®Google Scholar
• Yki-Jiirvinen H., Koivisto V. A. Natural course of insulin resistance in type I diabetes. N Engl J Med 1986; 315: 225–9
   Web of Science ®Google Scholar
• Madsbad S., Krarup T., Reguer L., Faber O. K., Binder C. Effect of strict blood glucose control on residual B-cell function in insulin-dependent diabetics. Diabetohgia 1981; 20: 530–4
   PubMed Web of Science ®Google Scholar
• Perlman K., Ehrlich R. M., Filler R. M., Albisser A. M. Sustained normoglycemia in newly diagnosed type I diabetic subjects. Diabetes 1984; 33: 995–1001
   PubMed Web of Science ®Google Scholar
• Shah S. C, Malone J. I., Simpson N. E. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. N Eml J Med 1989; 320: 550–4
   PubMed Web of Science ®Google Scholar
• Ludvigsson J., Heding L., Larsson Y., Leander E. C-peptide in juvenile diabetics beyond the postinitial remission period. Acta Paediatr Scand 1977; 66: 177–84
   PubMed Web of Science ®Google Scholar
• Steffes M., Tamborlane W., Becker D., Palmer J., Clea-Ry P., Bethseda M. D. The effect of intensive diabetes treatment on residual b-ccll function in the diabetes and complications trial (DCCT). Diabetes 1996; 45, Abstr. 59., for the DDCT Research Group, Suppl 2
   Web of Science ®Google Scholar
• Kämpe O., Andersson A., Björk E., Hallberg A., Karlsson F. A. High-glucose stimulation of 64,000 Mr islet cell autoantigen expression. Diabetes 1989; 38: 1326–8
   PubMed Web of Science ®Google Scholar
• Björk E., Kämpe O., Karlsson F. A., Pipeleers D. G., Andersson A., Hellerström C., Eizirk D. L. Glucose regulation of the autoantigen GAD65 in human pancreatic islets. J Clin Endocrinol Metab 1992; 75: 1574–6
   PubMedGoogle Scholar
• Björk E., Kämpe O., Gravé J., Hallberg A., Norheim I., Karlsson F. A. Modulation of beta-cell activity and its influence on islet cell antibody (ICA) and islet cell surface antibody (ICSA) reactivity. Autoimmunity 1993; 16: 181–8
   PubMed Web of Science ®Google Scholar
• Hagopian W. A., Karlsen A. E., Petersen J. S., Teague J., Gervassi A., Jiang J., Fujimoto W., Lernmark A. Regulation of glutamic acid decarboxylase diabetes autoantigen expression in highly purified isolated islets from Macaca nemestrina. Endocrinology 1993; 132: 2674–81
   PubMed Web of Science ®Google Scholar
• McCulloch D. K., Barmeier H., Neifing J. L., Palmer J. P. Metabolic state of the pancreas affects end-point titre in the islet cell antibody assay. Diabetologia 1991; 34: 622–5
   PubMed Web of Science ®Google Scholar
• Björk E., Kiimpe O., Andersson A., Karlsson F. A. Expression of the 64 kDa/GAD rat islet cell autoantigen is influenced by the rate of insulin secretion. Diabetologia 1992; 32: 490–3
   Web of Science ®Google Scholar
• Aguilar-Bryan L., Nichols C. G., Wechsler S. W., Clement J. P., IV., Boyd A. E., III., Gonzalez G., Herrera-Sosa H., Nguy K., Bryan J., Nelson D. A. Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science 1995; 268: 423–6
   PubMed Web of Science ®Google Scholar
• Inagaki N., Gonoi T., Clement J. P., IV., Namba N., Inazawa J., Gonzalez G., Aguilar-Bryan L., Seino S., Bryan J. Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science 1995; 270: 1166–70
   PubMed Web of Science ®Google Scholar
• Sturgess N. C, Ashford M. L., Cook D. L., Hales C. N. The sulphonylurea receptor may be an ATP-senitive potassium channel. Lancet 1985; ii: 474–5
   Google Scholar
• Trube G., Rorsman P., Ohno-Shosaku T. Opposite effects of tolbutamide and diazoxide on the ATP-dependent K+ channel in mouse pancreatic beta-cells. Pflugers Archiv 1986; 407: 493–9
   PubMed Web of Science ®Google Scholar
• Goode P. N., Farndon J. R., Anderson J., Johnston I. D., Morte J. A. Diazoxide in the management of patients with insulinoma. World J Surg 1986; 10: 586–92
   PubMed Web of Science ®Google Scholar
• Keller R. J., Eisenbarth G. S., Jackson R. A. Insulin prophylaxis in individuals at high risk of type 1 diabetes. Lancet 1993; 341: 927–8
   PubMed Web of Science ®Google Scholar
• Zhang Z. J., Davidson L., Eisenbarth G., Weiner H. L. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci USA 1991; 88: 10252–6
   PubMed Web of Science ®Google Scholar
• Björk E., Berne C., Kämpe O., Wibell L., Oskarsson P., Karlsson F. A. Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes. Diabetes 1996; 45: 1427–30
   PubMed Web of Science ®Google Scholar
• Fukuda M., Tanaka A., Tahara Y., Ikegami H., Yama-Moto Y., Kumahara Y., Sima K. Correlation between minimal secretory capacity of pancreatic 8-cells and stability of diabetic control. Diabetes 1988; 37: 81–8
   PubMed Web of Science ®Google Scholar
• Sjöberg S., Gunnarsson R., Gjötterberg M., Lefvert A. K., Persson A., Ostma J. Residual insulin production, glycemic control and prevalence of microvascular lesions and polyneuropathy in long-term type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1987; 30: 208–13
   PubMed Web of Science ®Google Scholar
• Nakanishi K., Kobayashi T., Inoko H., Tsuji K., Murase T., Kosaka K. Residual b-cell function and HLA-A24 in IDDM. Markers of glycemic control and subsequent development of diabetic retinopathy. Diabetes 1995; 44: 1334–9
   PubMed Web of Science ®Google Scholar